Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?

被引：4

作者：

Latagliata, Roberto ^{[1
]}

Breccia, Massimo ^{[1
]}

Carmosino, Ida ^{[1
]}

Cesini, Laura ^{[1
]}

De Benedittis, Daniela ^{[1
]}

Mohamed, Sara ^{[1
]}

Vozella, Federico ^{[1
]}

Molica, Matteo ^{[1
]}

Campanelli, Melissa ^{[1
]}

De Luca, Maria Lucia ^{[1
]}

Colafigli, Gioia ^{[1
]}

Quattrocchi, Luisa ^{[1
]}

Loglisci, Maria Giovanna ^{[1
]}

Massaro, Fulvio ^{[1
]}

Canichella, Martina ^{[1
]}

Diverio, Daniela ^{[1
]}

Mancini, Marco ^{[1
]}

Alimena, Giuliana ^{[1
]}

Foa, Robin ^{[1
]}

机构：

[1] Sapienza Univ Rome, Dept Cellular Biotechnol & Hematol, Policlin Umberto 1, Rome, Italy

来源：

EUROPEAN JOURNAL OF HAEMATOLOGY | 2018年 / 101卷 / 05期

关键词：

chronic myeloid leukemia; elderly; imatinib; prognosis; CHRONIC MYELOGENOUS LEUKEMIA; CML; SURVIVAL; THERAPY; LIFE; POPULATION; OUTCOMES; IMPACT; ADULTS; OLDER;

D O I：

10.1111/ejh.13110

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

ObjectivesTo evaluate differences in clinical results according to age among patients with chronic myeloid leukemia (CML). Methods207 consecutive CML patients treated with imatinib frontline were revised, dividing them in young adults (>20<45years) (YA), middle-aged adults (45<65years) (MA) and elderly (65years) (EL). ResultsCumulative incidence of complete cytogenetic response (CCyR) and major molecular response (MMolR) were significantly higher in MA compared with YA and EL (P<.001 for CCyR and P=.001 for MMolR). Number of total events was lower in MA (8 [11.1%] vs 21 [34.4%] in YA and 28 [37.8%] in EL, P=.001): no difference was observed for blastic evolution (P=.478). Number of deaths was higher in the EL (12 [16.2%] vs 2 [3.2%] in YA and 0 in MA, P<.001): however, 11/12 deaths in EL were not related to CML. The PFS curve in MA was significantly longer than in YA and in EL (P=.02). The OS curve in EL was significantly shorter than in YA and in MA (P<.001). ConclusionsAge at diagnosis influences significantly the course of CML patients treated with imatinib: a possible explanation of the counterintuitive worse course in YA is the delayed diagnosis compared to elderly.

引用

页码：578 / 584

页数：7

共 50 条

[41] Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV [J].

Michel, Christian ;

Burchert, Andreas ;

Hochhaus, Andreas ;

Saussele, Susanne ;

Neubauer, Andreas ;

Lauseker, Michael ;

Krause, Stefan W. ;

Kolb, Hans-Jochem ;

Hossfeld, Dieter Kurt ;

Nerl, Christoph ;

Baerlocher, Gabriela M. ;

Heim, Dominik ;

Bruemmendorf, Tim H. ;

Fabarius, Alice ;

Haferlach, Claudia ;

Schlegelberger, Brigitte ;

Balleisen, Leopold ;

Goebeler, Maria-Elisabeth ;

Haenel, Mathias ;

Ho, Anthony ;

Dengler, Jolanta ;

Falge, Christiane ;

Moehle, Robert ;

Kremers, Stephan ;

Kneba, Michael ;

Stegelmann, Frank ;

Koehne, Claus-Henning ;

Lindemann, Hans-Walter ;

Waller, Cornelius F. ;

Spiekermann, Karsten ;

Berdel, Wolfgang E. ;

Mueller, Lothar ;

Edinger, Matthias ;

Mayer, Jiri ;

Beelen, Dietrich W. ;

Bentz, Martin ;

Link, Hartmut ;

Hertenstein, Bernd ;

Fuchs, Roland ;

Wernli, Martin ;

Schlegel, Frank ;

Schlag, Rudolf ;

de Wit, Maike ;

Truemper, Lorenz ;

Hebart, Holger ;

Hahn, Markus ;

Thomalla, Joerg ;

Scheid, Christof ;

Schafhausen, Philippe ;

Verbeek, Walter .

HAEMATOLOGICA, 2019, 104 (05) :955-962

[42] Response and Adverse Effects of Nilotinib in Imatinib-resistant Chronic Myeloid Leukemia Patients: Data From a Developing Country [J].

Hussain, Shabneez ;

Shaikh, Mohammad Usman .

CLINICAL THERAPEUTICS, 2015, 37 (11) :2449-2457

[43] Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party [J].

Gugliotta, Gabriele ;

Castagnetti, Fausto ;

Palandri, Francesca ;

Breccia, Massimo ;

Intermesoli, Tamara ;

Capucci, Adele ;

Martino, Bruno ;

Pregno, Patrizia ;

Rupoli, Serena ;

Ferrero, Dario ;

Gherlinzoni, Filippo ;

Montefusco, Enrico ;

Bocchia, Monica ;

Tiribelli, Mario ;

Pierri, Ivana ;

Grifoni, Federica ;

Marzocchi, Giulia ;

Amabile, Marilina ;

Testoni, Nicoletta ;

Martinelli, Giovanni ;

Alimena, Giuliana ;

Pane, Fabrizio ;

Saglio, Giuseppe ;

Baccarani, Michele ;

Rosti, Gianantonio .

BLOOD, 2011, 117 (21) :5591-5599

[44] Clinical results with imatinib in chronic myeloid leukaemia [J].

Crossman, LC ;

O'Brien, S .

LEUKEMIA RESEARCH, 2004, 28 :S3-S9

[45] Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients [J].

Moon, Joon Ho ;

Sohn, Sang Kyun ;

Kim, Shi Nae ;

Park, Seon Yang ;

Yoon, Sung Soo ;

Kim, In Ho ;

Kim, Hyeoung Joon ;

Kim, Yeo Kyeoung ;

Min, Yoo Hong ;

Cheong, June Won ;

Kim, Jin Seok ;

Jung, Chul Won ;

Kim, Dong Hwan .

MEDICAL ONCOLOGY, 2012, 29 (02) :1179-1185

[46] Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States [J].

Abou Dalle, Iman ;

Kantarjian, Hagop ;

Burger, Jan ;

Estrov, Zeev ;

Ohanian, Maro ;

Verstovsek, Srdan ;

Ravandi, Farhad ;

Borthakur, Gautam ;

Garcia-Manero, Guillermo ;

Jabbour, Elias ;

Cortes, Jorge .

CANCER MEDICINE, 2019, 8 (15) :6559-6565

[47] Older patients with chronic myeloid leukemia (aparts per thousandyen65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV [J].

Proetel, Ulrike ;

Pletsch, Nadine ;

Lauseker, Michael ;

Mueller, Martin C. ;

Hanfstein, Benjamin ;

Krause, Stefan W. ;

Kalmanti, Lida ;

Schreiber, Annette ;

Heim, Dominik ;

Baerlocher, Gabriela M. ;

Hofmann, Wolf-Karsten ;

Lange, Elisabeth ;

Einsele, Hermann ;

Wernli, Martin ;

Kremers, Stephan ;

Schlag, Rudolf ;

Mueller, Lothar ;

Haenel, Mathias ;

Link, Hartmut ;

Hertenstein, Bernd ;

Pfirrmann, Markus ;

Hochhaus, Andreas ;

Hasford, Joerg ;

Hehlmann, Ruediger ;

Saussele, Susanne .

ANNALS OF HEMATOLOGY, 2014, 93 (07) :1167-1176

[48] Temporal effect of imatinib adherence on time to remission in chronic myeloid leukemia patients [J].

Clark, Samantha E. ;

Marcum, Zachary A. ;

Radich, Jerry ;

Etzioni, Ruth ;

Basu, Anirban .

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (08) :1343-1351

[49] Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation [J].

Kim, Dongho ;

Goh, Hyun Gyung ;

Kim, Soo-Hyun ;

Choi, Soo-Young ;

Park, Sa-Hee ;

Jang, Eun-Jung ;

Kim, Dong-Wook .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2012, 96 (01) :47-57

[50] Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib [J].

Swords, Ronan ;

Mahalingam, Devalingam ;

Padmanabhan, Swaminathan ;

Carew, Jennifer ;

Giles, Francis .

DRUG DESIGN DEVELOPMENT AND THERAPY, 2009, 3 :89-101

← 1 2 3 4 5 →